menu search
Trades24h logo
 Register
close Tap here to search
  1. Home

  2. News

  3. Stock Details

Subscribe To  

  Price Alert   Latest News   Economic Calendar News

ENVB / Enveric Biosciences to Participate in Upcoming Investor Conferences in February 2022

Enveric Biosciences to Participate in Upcoming Investor Conferences in February 2022
NAPLES, Fla. , Jan. 27, 2022 /PRNewswire/ - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-centric biotechnology company developing next-generation mental health and oncology treatments by leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body, today announced that Dr. Joseph Tucker, Chief Executive Officer of Enveric Biosciences, will participate in two upcoming investor conferences: Citi's Psychedelic Drug Call Series Tuesday, February 8 th at 10:00 a.m. Read More
Hmarkets Logo
Demo chevron_right Live Account chevron_right See Partner Details

Content Topics

Enveric

Biosciences

Participate

Upcoming

Investor

Conferences

February

Stock

ENVB

Posted: Jan 27 2022, 07:30
Author Name: PRNewsWire
Views: 110875

ENVB News  

Why Is Enveric Biosciences (ENVB) Stock Up 120% Today?

By InvestorPlace
May 18, 2023

Why Is Enveric Biosciences (ENVB) Stock Up 120% Today?

Enveric Biosciences (NASDAQ: ENVB ) stock is enlivened amid an otherwise soft early afternoon session on Wall Street, delivering triple-digit percenta more_horizontal

Enveric Biosciences to Present at the Gravitas Securities Inc. 6th Annual Growth Conference

By Business Wire
February 22, 2023

Enveric Biosciences to Present at the Gravitas Securities Inc. 6th Annual Growth Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the d more_horizontal

Enveric Biosciences to Present at the BIO CEO & Investor Conference

By Business Wire
February 1, 2023

Enveric Biosciences to Present at the BIO CEO & Investor Conference

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the more_horizontal

Enveric Biosciences to Present at the 6th Annual Neuroscience Innovation Forum and Biotech Showcase during

By Business Wire
December 21, 2022

Enveric Biosciences to Present at the 6th Annual Neuroscience Innovation Forum and Biotech Showcase during "J.P. Morgan Health Care Week 2023"

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the more_horizontal

Enveric Biosciences touts the publication of four patent applications for psychedelic-inspired drug candidates

By Proactive Investors
March 15, 2022

Enveric Biosciences touts the publication of four patent applications for psychedelic-inspired drug candidates

Enveric Biosciences (NASDAQ:ENVB) Inc announced that the company's first four Patent Cooperation Treaty (PCT) applications for the tryptamine family o more_horizontal

Enveric Biosciences files portfolio of patent applications for tryptamine derivatives

By Proactive Investors
March 1, 2022

Enveric Biosciences files portfolio of patent applications for tryptamine derivatives

Enveric Biosciences (NASDAQ:ENVB) announced that it has filed its tenth Patent Cooperation Treaty (PCT) application directed to tryptamine-based deriv more_horizontal

Enveric Biosciences files portfolio of patent applications for tryptamine derivatives

By Proactive Investors
March 1, 2022

Enveric Biosciences files portfolio of patent applications for tryptamine derivatives

Enveric Biosciences (NASDAQ:ENVB) announced that it has filed its tenth Patent Cooperation Treaty (PCT) application directed to tryptamine-based deriv more_horizontal

Enveric Biosciences files portfolio of patent applications for tryptamine derivatives

By Proactive Investors
March 1, 2022

Enveric Biosciences files portfolio of patent applications for tryptamine derivatives

Enveric Biosciences (NASDAQ:ENVB) announced that it has filed its tenth Patent Cooperation Treaty (PCT) application directed to tryptamine-based deriv more_horizontal

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

©2014-2024 All Rights Reserved. I.C

Hand-crafted & made with Love

logo close

Search within

Pages Search Results: